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Appropriately detoxified pertussis toxin (PT) of Bordetella pertussis is considered to be an essential
component of new-generation whooping cough vaccines, but the development of a procedure to obtain high
levels of purified toxin has been and continues to be a major difficulty. To produce a system enabling the
biological separation of PT from other virulence determinants of B. pertussis and the attainment of high yields
of the toxin, minitransposons containing the PT operon were constructed and stably integrated into the
chromosome of Bordetella virulence regulatory gene (bvg)-negative Bordetella bronchiseptica ATCC 10580.
Since the minitransposons introduced into Bordetella spp. lack the cognate transposase function, they are
unable to undergo further transposition events or mediate gene deletions and rearrangements that lead to strain
instability. The TnPtacPT minitransposon contains the PT operon under the control of the tac promoter and
directs IPTG (isopropyl-4-D-thiogalactopyranoside)-inducible expression of PT in B. bronchiseptica ATCC
10580. The level of IPTG-induced PT expression was, however, lower than that found for the wild-type B.
pertussis Tohama I strain. The TnfusPT minitransposon contains a promoterless PT operon which is only
expressed after insertion of the transposon downstream of an appropriately oriented indigenous promoter.
After "promoter probing" of B. bronchiseptica with the transposon, clones were screened for PT production
by immunoblotting with specific monoclonal antibodies. One clone, designated B. bronchiseptica 10580::
TnfusPTI, expresses significantly higher levels of PT than does B. pertussis Tohama I. The recombinant toxin
produced was biologically active in the Chinese hamster ovary cell-clustering assay. High-level expression ofPT
from a B. bronchiseptica host promoter should provide better yields of the toxin from bacteria not producing
other bvg-regulated pathogenesis factors that may play a role in the undesired side effects of current pertussis
vaccine preparations.
Increasing concern about side effects of immunization
with whole-cell preparations of Bordetella pertussis has, in
several countries, led to decreased acceptability of whoop-
ing cough vaccines and a consequent increase in the inci-
dence of the disease. It is imperative that an effective,
nonreactogenic vaccine of higher acceptability be devel-
oped. Potentially protective antigens that are candidates for
inclusion in a purified component vaccine include toxins,
such as pertussis toxin (PT) and adenylate cyclase, and
several cell surface or secreted antigens like filamentous
hemagglutinin (FHA) and serotype-specific fimbriae (33, 34).
Purification of antigens directly from B. pertussis is ham-
pered by phase variation controlled by the bvg (Bordetella
virulence gene) positive regulatory locus (12, 19, 49), the
presence of reactogenic contaminants, poor bacterial growth
rates, and low yields from this nutritionally fastidious micro-
organism. To circumvent these problems, attempts have
been made to obtain expression of recombinant antigens in
Escherichia coli by using strong transcriptional and transla-
tional signals. The five genes encoding PT have been sepa-
rately cloned and expressed in E. coli under the control of
the lambda PL promoter (6). The serotype 2 fimbrial subunit
has also been expressed from the lambda PL and PR promot-
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ers (47). In both cases, the recombinant proteins failed to
assemble into products that were immunologically identical
to the native antigens. Recombinant serotype 2 fimbriae
have been produced in Bordetella parapertussis and Borde-
tella bronchiseptica strains under the control of the native
B. pertussis promoter and in B. bronchiseptica under the
control of the lac promoter (46). Pertussis holotoxin has
also been produced in recombinant B. parapertussis and
B. bronchiseptica strains under the control of the original
B. pertussis promoter, although the level of expression
obtained was less than that in wild-type B. pertussis and
such expression remained subject to modulation and bvg-
controlled phase variation. Recombinant broad-host-range
plasmids carrying the PT operon were also extremely unsta-
ble, being subject to both plasmid loss and gene deletions
(21).
Pertussis toxoid will be a central component of new-
generation vaccines, and the development of a system for
the stable production of high yields of toxin free of poten-
tial reactogenic virulence determinants which may play a
role in the observed side effects of pertussis vaccination is a
major preoccupation of a number of laboratories. In this
report, we describe the construction of minitransposons for
the stable expression of native pertussis holotoxin in a
bvg-negative strain of B. bronchiseptica. This strategy, in
combination with methods for the genetic detoxification of
PT (18, 23, 30), should provide a source for the production of
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a highly purified nonreactogenic acellular vaccine compo-
nent.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. B. pertussis To-
hama I (serotype 1.2) fim+ fha+ (40) and B. bronchiseptica
5376 fim+ fha+ were obtained from R. Brownlie; B. bron-
chiseptica ATCC lOS80fimfha was obtained from M. Hofle.
E. coli JM109 endAl recA hsdR supE thi gyr lac-pro F'
tra-36 proAB lacPZ M15 was used as the recipient strain in
cloning steps not involving pUT derivative plasmids (51); E.
coli CC118(Apir) was used as the recipient strain for pUT
derivatives (14); E. coli SM10(Apir) (27) was used to mobilize
pUT derivatives (8, 14) to B. bronchiseptica. The plasmids
used in this work were pRK600 (9), pDSK519 (17), and
pUC18 (51). pRMB2 (4, 25) was used as a source of the bvg
operon. pTX42 (22) was a kind gift from J. Keith and was
used as a source of the PT operon, pUC18NotI (14),
pUT::miniTnS/Km (8), and pUT::TnPtac, which was con-
structed by V. De Lorenzo.
E. coli was grown on Z agar (45), X-Gal (5-bromo-4-
chloro-3-indolyl-p-D-galactopyranoside) medium (24), and
Luria broth (24), and Bordetella spp. were grown on BG agar
or in SS broth (43). Where appropriate, strains were grown
with 0.2% cyclodextrin, 100 ,ug of ampicillin per ml, 50 ,ug of
cephalexin per ml, or 50 jig of kanamycin per ml. IPTG(isopropyl-,-D-thiogalactopyranoside) induction was carried
out by the addition of 1.0 mM IPTG. Bacterial cultures were
routinely grown at 37°C. Liquid cultures were aerated by
shaking at 300 rpm in a New Brunswick Environmental
Incubator Shaker.
DNA manipulations. Restriction endonucleases, T4 DNA
ligase, and polynucleotide kinase were used essentially as
described by Maniatis et al. (24). Plasmids were isolated by
alkaline lysis (24). Transformation was carried out as de-
scribed by Hanahan (13). Agarose gel electrophoresis was
performed as previously described (45). Southern transfer
and DNA hybridization with nick-translated DNA as a probe
were performed as described by Maniatis et al. (24). Chro-
mosomal DNA was isolated as described previously (32).
DNA sequencing was carried out by the chain termination
method (37). Taq polymerase (Boehringer) was used as
described by Scharf (41). The polymerase chain reaction
(PCR) primers PT-5'XbaI (5'-GGTCTAGAATCAAAACG
CAGAGGGGAAGA-3') and PT-3'XbaI (5'-CCAGGTCTA
GAACGAATA-3') used for cloning the transcriptional start
site (31) and S1 subunit cistron of the PT operon as an XbaI
fragment (XbaI sites are underlined) were synthesized by
using an Applied Biosystems model 380B DNA synthesizer
in accordance with the manufacturer's instructions.
Transfer of plasmids to B. bronchiseptica. E. coli strains
containing both pRK600 and pDSK519 derivatives or E. coli
SM10(Apir) containing pUT derivatives was grown overnight
in nutrient broth with antibiotic selection. A 1.0-ml sample of
culture was pelleted by centrifugation at 3,000 x g for 15 min
and resuspended in 1.0 ml of 0.9% NaCl. The suspension
was used to overlay 1-day-old plate cultures of B. bronchi-
septica, and the plates were incubated for 4 h at 37°C. The
mating mixtures were then plated, selecting for B. bronchi-
septica recombinants with cephalexin (contraselection
against the E. coli donor strain) and kanamycin (selection for
the plasmid or minitransposon).
Protein purification and analysis. Whole-cell extracts of
Bordetella spp. were prepared by resuspending cells in
sample buffer (60 mM Tris-HCI [pH 6.8], 1% sodium dodecyl
sulfate, 1% 2-mercaptoethanol, 10o glycerol, 0.01% bro-
mophenol blue) and boiling for 5 min. Samples were electro-
phoresed by the method of Laemmli (20) by using a 3.85%
acrylamide stacking gel and a 15% acrylamide separating gel.
PT isolated from B. pertussis was a kind gift from S. Cryz.
Recombinant PT from B. bronchiseptica ATCC 10580 was
partially purified from periplasmic extracts (21) by using
heparin Sepharose CL-6B chromatography by the method of
Megret and Alouf (26). Chinese hamster ovary (CHO) cell-
clustering assays were performed to ascertain the biological
activity of recombinant PT as previously described (11, 15).
Inhibition of CHO cell clustering with protective monoclonal
antibodies was carried out essentially as described by Sato et
al. (39). Protein concentration was determined by the
method of Bradford (3).
Immunological techniques. Monoclonal antibodies E19,
E205, and E251 (48), which provided protection against PT
clustering of CHO cells and were reactive against PT sub-
units S1 (E19), S4 (E205), and S2 and S3 (E251), were raised
against detoxified PT (29) by using standard techniques (39).
Monoclonal antibody P12H3 to FHA was previously de-
scribed (10). Western blotting (immunoblotting) was carried
out essentially as described by Burnette (5). Proteins were
transferred to a nitrocellulose membrane by using 25 mM
Tris-192 mM glycine-20% methanol (pH 8.3) as a transfer
buffer and a 10% solution of 0.3% low-fat milk in phosphate-
buffered saline (PBS) (pH 7.4) as a blocking reagent. A
cocktail of appropriately diluted E19, E205, and E251 hy-
bridoma supernatant fluid was used as the first antibody. The
detection system used was Bio-Rad horseradish peroxidase-
conjugated goat anti-rabbit or goat anti-mouse immunoglob-
ulin G (IgG) with 4-chloro-1-naphthol as substrate. Colony
immunoblotting was carried out by performing colony lifts
onto nylon membranes (Biodyne A, Pall), baking the filters
at 65°C, and then performing essentially the same procedure
as Western blotting after the transfer step. Dot immunoblot-
ting was carried out by heat inactivation of a sample of the
bacterial culture (grown at 37°C with shaking in 200 ml of
SS-X medium) at 65°C for 15 min, spotting 50 p.l of the
culture onto a nylon membrane (Biodyne A, Pall), and then
performing essentially the same procedure used for Western
blotting after the transfer step. For immunoelectron micros-
copy, antibodies were purified from rabbit antisera raised
against pertussis toxoid (29) by using a protein A-Sepharose
CL-4B column (Pharmacia) as described in the manufac-
turer's instructions.
Electron microscopy. For fimbrial labeling, thin carbon
support film was prepared by indirect sublimation of carbon
onto freshly cleaved mica. By using 400-mesh copper grids,
the respective strains were then negatively stained with 4%
(wt/vol) uranyl acetate (pH 4.5) by the procedure of Valen-
tine et al. (44). For whole-cell labeling, bacterial strains
grown on plates were gently suspended in 250 ,u1 of PBS,
absorbed onto freshly prepared collodium-covered nickel
grids, and then rinsed with distilled water. After air drying,
the grids were treated with a 1:25 dilution of the purified
PT-specific IgG antibody (200 ,ug of IgG protein per ml) for
30 min at room temperature. Unbound antibody was re-
moved with a mild spray of PBS from a plastic bottle. The
bound antibodies were made visible for electron microscopic
examination by incubating the grids on drops of protein
A-gold complexes (10-nm gold particle size at an optical
density at 520 nm of 0.01) for 10 min at room temperature.
The protein A-gold complexes were prepared by established
procedures (42). The grids were subsequently rinsed with a
mild spray of PBS containing 0.01% Tween 20 and then with
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somal DNA isolated from B. bronchiseptica 5376 (lane 1), B.
bronchiseptica ATCC 10580 (lane 2), and B. pertussis Tohama I
(lane 3). The sizes of reacting bands are given in kilobases.
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an electron microscope. For postembedding labeling, cells of
S,.,. ...F+sj4l the respective strains were fixed directly in the nutrient
broth by use of a fixative solution containing 0.5% (vollvol)
formaldehyde and 0.3% (vol/vol) glutaraldehyde in PBS for 1
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the samples were embedded into 1.5% (wt/vol) agar, and
after solidification of the agar, small cubes were cut and
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Vreulencey the bound antibodies were made visible with protein A-gold
pMWI 32 regulatory) complexes (10-nm gold particle size; 30-mmn incubation13.4l (Btime). Subsequently, the sections were washed with PBS
containing 0.01% Tween 20 and the sections were air dr'ed
mob prior to poststaining with 4% (wt/vol) uranyl acetate for 3
min. Electron micrographs were examined and micrographs
were taken with a Zeiss electron microscope EM lOB at an
EcoRlkisw acceleration voltage of 80 kV and at calibrated magnifica-
tions.
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RESULTS
Characterization of B. bronchiseptica 5376 and ATCC
10580. The Bordetella virulence regulatory genes (bvg) co-
ordinately regulate a number of virulence determinants of
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FIG. 2. Construction of broad-host-range hybrid plasmids specifying PT expression controlled by the native B. pertussis promoter
(pMW120) and lac promoter (pMW124). The PT operon was cloned from plasmid pTX42 (22). PT subunit genes Si to S5 (open arrows) and
the PT promoter (filled arrow) are indicated. The broad-host-range plasmid vector pDSK519 contains the mob site of pRSF1010 (mob; filled
box), lac promoter (PLAC; filled arrow), P-galactosidase a fragment sequence (P-gal; open box), and kanamycin resistance gene (Kan; open
box). Plasmid pUC18 (51) contains the lactose repressor gene (Lacd; open box), ampicillin resistance gene (Amp; open box), lac promoter,
and 3-galactosidase a fragment sequence (as described for pDSK519). The direction of transcription is indicated by either thin arrows or the
orientation of open arrows. Plasmids are not drawn to scale, and only relevant restriction sites are shown.
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FIG. 3. Analysis of PT expression by B. bronchiseptica 5376
recombinants. Whole-cell extracts of bacteria containing pDSK519
(lane 1), pMW120 (lane 2), and pMW124 (lane 3) are shown, as are
an extract of B. pertussis Tohama I (lane 4) and purified PT (lane 5).
(A) Coomassie blue-stained gel of whole-cell extracts; (B) Western
blot analysis of whole-cell extracts by using anti-PT monoclonal
antibodies E19, E205, and E251. The positions of the PT subunits Si
to S5 are indicated by arrows.
the genus Bordetella, including FHA and serotype-specific
fimbriae (19, 49). It would be advantageous to produce
pertussis vaccine components in bvg-negative Bordetella
spp. and hence achieve the biological separation of vaccine
components from other bvg-regulated virulence factors that
may play a role in the observed side effects of whole-cell
vaccines. The B. bronchiseptica strains used in this work
were studied for the production of FHA and fimbriae to
determine the bvg status of these strains. By using electron
microscopy and the anti-FHA monoclonal antibody P12H3
in Western blots, it was found that strain 5376 produced both
fimbriae (Fig. 1A) and FHA (results not shown). On the
other hand, strain ATCC 10580 failed to express either of
these bvg-regulated genes (Fig. 1B and results not shown).
However, the latter strain converted to a Fim+ (Fig. 1C)
Fha+ (results not shown) phenotype through acquisition of
pMW132 (Fig. 1D), a plasmid constructed by insertion of the
B. pertussis bvg operon present in pRMB2 (4, 25) into the
broad-host-range vector pDSK519. After transfer of this
plasmid to ATCC 10580, transconjugants were found to have
a small-colony morphology as previously noted by other
workers (25, 28). B. bronchiseptica bvg-negative derivatives
can arise through spontaneous small deletions or frameshift
mutations occurring in the bvg locus (28). However, no
obvious deletion of the bvg operon of ATCC 10580 could be
detected by Southern hybridization of EcoRI-digested chro-
mosomal DNA by using the cloned bvg determinant as a
probe (Fig. 1E), indicating that a deletion of less than 100 bp
(which would be undetectable by Southern analysis) or a
frameshift mutation had occurred.
Broad-host-range plasmid-based expression of PT from the
lac promoter and native B. pertussis promoter. The PT operon
was subcloned into the broad-host-range plasmid pDSK519
to assess the utility of the lac promoter and the native B.
pertussis promoter in B. bronchiseptica. The complete PT
operon was cloned as an EcoRI-BamHI fragment to produce
pMW120, in which the PT operon is oriented counter to that
of the lac promoter. Plasmid pMW121 contains the XbaI-
BamHI fragment containing the S2-, S4-, S5-, and S3-subunit
cistron part of the operon inserted into pDSK519, such that
these cistrons are read from the lac promoter. Primers
PT-5'XbaI and PT-3'XbaI were used in a PCR amplification
experiment to isolate a DNA fragment containing the tran-
scriptional start site of the PT operon (31), and the S1
subunit cistron, flanked by XbaI sites, was cloned into
pUC18 to produce pMW123. This XbaI fragment was sub-
sequently ligated to the genes encoding the S2, S4, S5, and
S3 subunits contained within pMW121 to construct
pMW124, which contains the PT operon under the control of
the lac promoter (Fig. 2). Plasmids pDSK519, pMW120, and
pMW124 were transferred to B. bronchiseptica 5376 and
analyzed for PT expression. Although the lac promoter
directed significantly greater levels of PT than the native B.
pertussis bvg-regulated promoter, these constructions did
not attain the level of PT production found in B. pertussis
Tohama I (Fig. 3). PT expression from pMW124 was not
influenced by the presence or absence of 1 mM IPTG,
indicating that this strain did not contain a lac repressor that
could regulate the lac promoter (results not shown).
Construction of the minitransposons TnPtacPT and Tnfus-
PT and their integration into the chromosome of B. bronchi-
septica ATCC 10580. Minitransposons containing the PT
operon were constructed to hyperexpress PT in bvg-negative
B. bronchiseptica ATCC 10580. The PT operon was cloned
from pMW124 into pUC18NotI to provide flanking NotI
sites for insertion into the pUT::miniTnS chromosomal inte-
gration system. The promoterless PT operon was subcloned
from pMW125 as a NotI fragment in the same orientation as
the tac promoter of pUT: :TnPtac to form pMW126 (TnPtac-
PI) and in the opposite orientation in pUT::miniTn5/Km to
produce pMW127 (TnfusPT) (Fig. 4). After mobilization of
pMW126 and pMW127 from E. coli to B. bronchiseptica
ATCC 10580, transconjugants were screened for PT produc-
tion (by colony immunoblotting and Western blotting) and
loss of the suicide vector (by kanamycin resistance and
ampicillin sensitivity). The levels of PT expression by dif-
ferent TnPtacPT transconjugants (including one transconju-
gant designated ATCC 10580::TnPtacPTJ) were similar and
were less than that by B. pertussis (Fig. 5); PT expression
was dependent upon the presence of IPTG (results not
shown). On the other hand, fewer than 10% of transconju-
gants containing TnfusPT expressed PT, and the level of PT
expression in those that did varied greatly (results not
shown), as would be expected from "promoter probing"
with a transposon designed to produce transcriptional fu-
sions between native promoters and the promoterless PT
operon. One selected TnfusPT transconjugant (ATCC
10580: :TnfusPTI) directed substantially higher levels of PT
expression than did B. pertussis (Fig. 5). To confirm the
chromosomal location of both TnPtacPTJ and TnfusPTJ and
the loss of the suicide vector, total DNA from ATCC 10580,
ATCC 10580::TnPtacPTI, and ATCC 10580::TnfusPTI was
digested with EcoRI and subjected to Southern hybridization
analysis by using pMW126 as a probe (Fig. 6). The loss of the
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FIG. 4. Construction of suicide vectors containing minitransposons for PT expression under the control of the tac promoter (pMW126) and
as transcriptional fusions with native promoters (pMW127). Symbols representing the PT subunits Si to S5, lac promoter, lactose repressor
gene, ,-galactosidase a subunit sequence, mob site, kanamycin resistance gene, and ampicillin resistance gene are as described in the legend
to Fig. 2. Plasmid pUT::miniTnS/Km and pUT::TnPtac contain the IS50R transposase (tnp; filled box) and TnS 19-bp terminal ends (short,
filled boxes) flanking the kanamycin resistance gene of pUT::miniTn5/Km and flanking the kanamycin resistance gene, lactose repressor gene,
and tac promoter (Ptac; filled arrow) of pUT::TnPtac. The Tn5 terminal ends delineate the minitransposons TnPtacPT (pMW126) and TnfusPT
(pMW127). Plasmids are not drawn to scale, and only relevant restriction sites are shown.
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FIG. 5. Analysis of PT expression by minitransposon-containing
derivatives of B. bronchiseptica ATCC 10580. Whole-cell extracts
of bacteria lacking TnPtacPTI and TnfusPTI (lane 1) or containing
TnPtacPTi (lane 2) or TnfusPTi (lane 3) are shown, as are extracts
of B. pertussis Tohama I (lane 4) and purified PT (lane 5). (A)
Coomassie blue-stained gel of whole-cell extracts; (B) Western blot
analysis of whole-cell extracts, using anti-PT monoclonal antibodies
E19, E205, and E251. The positions of the PT subunits S1 to S5 are
indicated by arrows.
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pUT suicide vector was confirmed. For TnfusPTI, the next
available EcoRI site upstream of the PT operon was pro-
vided by the chromosomal DNA sequence. The cryptic PT
operon of B. bronchiseptica (1) was also detected.
Characterization of PT expression in B. bronchiseptica
ATCC 10580::TnfusPTI. The stabilities of plasmid-encoded
PT (pMW124) and transposon-encoded PT (TnfusPTJ) ex-
pressed in ATCC 10580 were compared after growth in SS-X
medium (Table 1). Clearly, even after 60 generations without
antibiotic selection, transposon-encoded PT appeared to be
stable. On the other hand, plasmid-encoded PT was very
unstable. PT production was 100% linked to kanamycin
resistance in strains containing or having previously con-
tained pMW124, indicating that internal deletions of the PT
operon had not occurred. Growth rates and levels of PT
production in ATCC 10580, ATCC 10580::TnfusPTI, and B.
TABLE 1. Stability of PT expression from B. bronchiseptica
ATCC 10580(pMW124) and ATCC 10580: :TnfusPTl
after 60 generations without antibiotic selection
No. of bacteria/mIa % PTpo % LinkageStrain Sb~5 of PT toCpr Cpr Kmr ducers Kmrc
ATCC 10580(pMW124) 2.1 x 109 3.0 x 105 <1 100
ATCC 10580::TnfusPTJ 3.0 x 109 2.9 x 109 100 100
a Strains were cultured for 60 generations without kanamycin selection and
then plated with selection for cephalexin (Cp) alone or in combination with
kanamycin (Km).
b A total of 100 Cpr colonies were screened for PT production by colony
immunoblotting.
c A total of 100 Cpr Kmr colonies were screened for PT production by
colony immunoblotting.
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FIG. 6. Southern hybridization analysis of B. bronchiseptica
ATCC 10580 containing minitransposons. (A) Diagrammatic repre-
sentation of the PT operon, TnPtacPT, and TnfusPT. Symbols are
as described in the legend to Fig. 4; only EcoRI restriction sites are
shown. (B) Southern blot, using pMW126 as a probe, of EcoRI-
digested chromosomal DNA isolated from ATCC 10580 (lane 1),
ATCC 10580::TnPtacPTI (lane 2), and ATCC 10580::TnfusPTI
(lane 3). Plasmid pMW126 DNA digested with EcoRI was also
included (lane 4). Molecular size markers (given in kilobases) and
the origins of reacting bands, as described in panel A, are indicated
by arrows.
pertussis Tohama I were analyzed (Fig. 7A and B). Although
the growth rate of B. bronchiseptica ATCC 10580: :TnfusPTJ
was slower than that of the nonmutant parent strain ATCC
10580, the transposon-containing strain still grew signifi-
cantly faster than B. pertussis (Fig. 7A). Moreover, high
levels of surface-expressed recombinant PT produced from
B. bronchiseptica were detected after 18 h of growth,
whereas equivalent amounts ofPT were only produced by B.
pertussis after 36 h of growth (Fig. 7B). Recombinant PT was
localized by using immunoelectron microscopic techniques
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FIG. 7. Characterization of B. bronchiseptica ATCC 10580::TnfusPT. (A) Growth curves of B. pertussis Tohama I (filled circles), B.
bronchiseptica ATCC 10580 (open triangles), and ATCC 10580::TnfusPTI (open squares). (B) Dot immunoblots of cultures of (i) ATCC 10580,
(ii) ATCC 10580::TnfusPTl, and (iii) B. pertussis Tohama I taken from panel A at 12, 18, 24, 30, 36, 42, 54, 63, and 84 h (dots 1 to 9,
respectively). The blot was probed with the anti-PT monoclonal antibodies E19, E205, and E251. (C to H) Electron microscopic localization
of PT. Whole cells (C, E, and G) and thin sections (D, F, and H) of Tohama I (C and D), ATCC 10580 (E and F), and ATCC 10580: :TnfusPTI
(G and H) after protein A-gold labeling with anti-PT rabbit polyclonal antibodies are shown. Note in panel H that labeling of ATCC
10580::TnfusPTJ thin sections is stronger at the periphery of the cells. Bars, 2 ,Lm. Symbol: G, protein A-gold complexes (indicated by
arrows).
in the periplasm and on the cell surface of ATCC
10580: :TnfusPTJ (Fig. 7C to H). Unlike the situation with B.
pertussis (16) and recombinant bvg-positive B. parapertussis
and B. bronchiseptica (21), which secrete PT into the me-
dium, detectable levels of PT were not found in the super-
natant fluid of cultures of ATCC 10580: :TnfusPTJ even after
growth in medium supplemented with 0.2% cyclodextrin
(results not shown).
Periplasmic extracts of ATCC 10580::TnfusPTI were sub-
jected to heparin Sepharose CL-6B chromatography as
A
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FIG. 8. Characterization of recombinant PT. (A) Western blot analysis, using anti-PT monoclonal antibodies E19, E205, and E251, of
recombinant PT eluted after heparin Sepharose chromatography of periplasmic extracts of B. bronchiseptica ATCC 10580::TnfusPTI (lane
1) and purified wild-type PT (lane 2). The positions of the PT subunits Si to S5 are indicated by arrows. (B to G) Determination of CHO
cell-clustering activity of recombinant PT. CHO cell-clustering assays without PT (B and E) or with recombinant PT (C and D) or wild-type
PT (F and G) are shown. Panels D, E, and G also contain monoclonal antibody E19.
previously described (26). Compared with pertussis holo-
toxin prepared from B. pertussis, these preparations con-
tained relatively higher levels of PT subunits S3 and S4 (Fig.
8A). Witvliet et al. (50) have shown that the S3-S4 dimer
contains a carbohydrate binding receptor. Perhaps the pre-
ponderance of S3 and S4 reflects efficient binding of the
S3-S4 dimer to heparin, a linear glycosaminoglycan (26). Si
and S2 (and presumably S5, which was not detected because
of the lack of an anti-S5 antibody) were coeluted with S3 and
S4 from the heparin column, suggesting that recombinant
holotoxin is formed in the bacterial periplasm. To determine
if this was the case, recombinant PT preparations were
assayed for biological activity by use of the CHO cell-
clustering assay. Since our recombinant PT preparations
contained proteins other than PT subunits after heparin
chromatography (results not shown), monoclonal antibody
E19, which specifically binds to the Si subunit of PT and
inhibits CHO cell clustering by PT, was used to demonstrate
the specificity of any biological activity of the toxin prepa-
ration. Tested wild-type and recombinant pertussis holotox-
ins were adjusted to similar S1 subunit concentrations as
assessed by comparative Western blot analysis (results not
shown). As shown in Fig. 8B and C, recombinant PT
produces the same morphological effect as PT isolated from
B. pertussis (Fig. 8E and F), at equivalent concentrations,
and this activity was specifically inhibited by monoclonal
antibody E19 (Fig. 8D and G).
DISCUSSION
Previous efforts to produce recombinant PT include
expression of separate PT subunits in E. coli (6) and Bacillus
subtillus (36, 38) and pertussis holotoxin in B. parapertussis
and B. bronchiseptica (21). PT subunits expressed sepa-
rately in E. coli were nonprotective as assessed in a standard
animal model (6). Plasmid-specified PT expression in Borde-
tella spp. was found to be unstable, gave low product yields,
and was subject to phase variation (21). In this report we
describe the stable, high-level expression of PT in bvg-
negative B. bronchiseptica. The use of such strains offers
several advantages for the production of PT for vaccine
purposes, including fast bacterial growth rates, high yields,
and the absence of other bvg-controlled virulence determi-
nants in PT preparations.
The PT operon was cloned by using PCR methodology to
construct minitransposons (8, 14). The transposase function
is lost with the suicide delivery vehicle, which ensures that
further transposition and transposon-mediated gene dele-
tions and rearrangements do not occur (8, 14). TnPtacPT
contains the PT operon under the control of the tac pro-
moter. IPTG-inducible expression of PT in ATCC 10580
from this transposon was detected, although the observed
level of PT expression was lower than that for wild-type B.
pertussis Tohama I. The tac promoter, although functional
in B. bronchiseptica, is apparently not very efficient. An-
other transposon, TnfusPT, which contains a promoterless
PT operon, was constructed. After transcriptional fusion to
a native B. bronchiseptica promoter, this minitransposon
expressed significantly higher levels of PT than did B.
pertussis Tohama I. The identification and characterization
of strong promoters of B. bronchiseptica by promoter prob-
ing methods could obviously lead to the development of
minitransposons similar to TnPtac containing such promot-
ers that direct high levels of expression of pertussis vaccine
components in Bordetella spp. Because of the lack of
transposon immunity in the minitransposon system (8, 14),
the use of minitransposons containing different antibiotic
resistance markers (8, 14) could yield bvg-negative strains
containing multiple insertions, thereby creating vaccine pro-
duction strains capable of yielding multiple antigens. In a
study of the stability of plasmid-encoded PT (pMW124) and
minitransposon-encoded PT (TnfusPTI), it was found that
after 60 generations without antibiotic selection, less than
1% of tested bacteria contained the plasmid (pMW124) or
produced PT, whereas 100% of bacteria still contained
TnfusPTI and expressed PT. Other workers have also
shown that plasmids derived from pLAFR2 or pRSF1010
and encoding the native PT operon are unstable (21).
PT active in the CHO cell-clustering assay was produced
by B. bronchiseptica ATCC 10580::TnfusPTJ. Burns et al.
(7) have shown that this morphological response requires
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association of the Si subunit with the B oligomer (S2 to S5).
The induction of low-level CHO cell clustering by individual
components that has been observed was most likely due to
cross-contamination with the S1 subunit or the B oligomer,
since recombinant Si subunit purified from E. coli fails to
exhibit any CHO cell-clustering activity yet restores purified
B oligomer to full toxic activity (2). Periplasmic extracts
prepared from B. bronchiseptica ATCC 10580::TnfusPTJ
bacteria contained recombinant PT exhibiting CHO cell-
clustering activity, demonstrating that pertussis holotoxin is
formed in the periplasm of the bvg-negative production
strain. Periplasmic extracts contain both recombinant per-
tussis holotoxin and PT dimers (S3-S4), indicating that
holotoxin and dimer formation are not dependent on bvg-
regulated gene products. However, unlike the case with B.
pertussis (16) and recombinant bvg-positive B. parapertussis
and B. bronchiseptica (21), holotoxin was not secreted from
growing bacteria. To determine whether PT secretion is
controlled by a bvg-regulated secretion system, we are
currently constructing isogenic bvg-positive and bvg-nega-
tive strains of Bordetella spp. which express PT. The iden-
tification and cloning of genes involved in PIT secretion and
their expression in B. bronchiseptica would further facilitate
the purification of recombinant PIT.
Genetically detoxified analogs of PT, expressed in either
B. pertussis or B. parapertussis, have been developed by
several groups (18, 23, 30). We expect that the production of
detoxified PT in bvg-negative B. bronchiseptica would be
accompanied by the same benefits (i.e., increased bacterial
growth rates, stable expression, high yields, the absence of
other bvg-controlled virulence determinants in PT prepara-
tions, and the lack of phase variation) as those described
here for recombinant PT. Experiments designed to express
genetically detoxified PT in bvg-negative B. bronchiseptica
are currently in progress.
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